<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.117467</article-id><article-id pub-id-type="publisher-id">ACM-44147</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210700000_12963713.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  上尿路尿路上皮癌术后出现膀胱复发的危险因素分析
  Risk Factors for Intravesical Recurrence after the Surgery of Upper Tract Urothelial Carcinoma
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>韩</surname><given-names>克威</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>于</surname><given-names>芹超</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>翔宇</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>裴</surname><given-names>兴超</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>青岛大学附属医院崂山院区泌尿外科，山东 青岛</addr-line></aff><aff id="aff2"><addr-line>青岛大学青岛医学院，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>07</month><year>2021</year></pub-date><volume>11</volume><issue>07</issue><fpage>3218</fpage><lpage>3224</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：探讨上尿路尿路上皮癌(UTUC)患者行根治术后出现膀胱复发的危险因素。方法：收集2015年1月份到2016年12月份在青岛大学附属医院行患侧肾输尿管全长切除术加膀胱袖套状切除术的总共127例UTUC患者的临床资料，分析患者的基线数据、术后病理结果、随访数据等资料，采用卡方检验及logistics回归分析UTUC患者行根治术后出现膀胱复发的危险因素。结果：本研究中，在127例行UTUC根治术的患者中，共28例出现了膀胱复发，复发率为22.0% (28/127)，其中67.9% (19/28)的患者膀胱初次复发出现在术后2年内。患者的年龄、性别、肿瘤的侧别、位置、直径以及术后病理的分期和分级这7项因素的差异无统计学意义(P &gt; 0.05)。而术前进行输尿管镜检、合并膀胱癌病史的患者术后出现膀胱复发的差异有统计学意义(P &lt; 0.05)，视为膀胱复发的危险因素。将上述危险因素纳入logistics回归分析，发现其均为UTUC根治术后出现膀胱复发的独立危险因素。结论：术前行输尿管镜检查、合并膀胱癌病史是UTUC根治术后出现膀胱复发的独立危险因素。临床医师应着重关注存在上述危险因素的UTUC术后患者，做好定期随访。
   Objective: To investigate the risk factors for intravesical recurrence in patients after the surgery of upper tract urothelial carcinomas (UTUCs). Methods: Clinical data of 127 UTUC patients were collected who underwent full-length nephroureter plus bladder sleeve resection in Affiliated Hospital of Qingdao University during Jan. 2015 to Dec. 2016. The baseline data, postoperative pathological results and follow-up data were analyzed. Chi-square test and logistic regression were used to analyze the risk factors of intravesical recurrence in patients with UTUC after the surgery. Result: In this study, 28 cases of 127 patients were diagnosed intravesical recurrence after radical operation of UTUC, the recurrence rate was 22.0% (28/127), of which 67.9% (19/28) patients had intravesical recurrence within 2 years after operation. There was no significant difference in the incidence of intravesical recurrence among different gender, age, tumor location and size, pathological stage and tumor side (P &gt; 0.05). There was a significant difference in intravesical recurrence between patients undergoing ureteroscopy before the surgery and a history of bladder cancer before operation (P &lt; 0.05), which was regarded as a risk factor for intravesical recurrence. Logistic regression analysis showed that the above risk factors were independent risk factors for intravesical recurrence after radical operation of UTUC. Conclusion: Ureteroscopy before the surgery and history of bladder cancer are independent risk factors for intravesical recurrence after UTUC radical resection. Clinicians should pay more attention to the patients with the above risk factors after UTUC, and make regular follow-up.
 
</p></abstract><kwd-group><kwd>上尿路尿路上皮癌，膀胱复发，危险因素, Upper Tract Urothelial Carcinoma</kwd><kwd> Intravesical Recurrence</kwd><kwd> Risk Factor</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨上尿路尿路上皮癌(UTUC)患者行根治术后出现膀胱复发的危险因素。方法：收集2015年1月份到2016年12月份在青岛大学附属医院行患侧肾输尿管全长切除术加膀胱袖套状切除术的总共127例UTUC患者的临床资料，分析患者的基线数据、术后病理结果、随访数据等资料，采用卡方检验及logistics回归分析UTUC患者行根治术后出现膀胱复发的危险因素。结果：本研究中，在127例行UTUC根治术的患者中，共28例出现了膀胱复发，复发率为22.0% (28/127)，其中67.9% (19/28)的患者膀胱初次复发出现在术后2年内。患者的年龄、性别、肿瘤的侧别、位置、直径以及术后病理的分期和分级这7项因素的差异无统计学意义(P &gt; 0.05)。而术前进行输尿管镜检、合并膀胱癌病史的患者术后出现膀胱复发的差异有统计学意义(P &lt; 0.05)，视为膀胱复发的危险因素。将上述危险因素纳入logistics回归分析，发现其均为UTUC根治术后出现膀胱复发的独立危险因素。结论：术前行输尿管镜检查、合并膀胱癌病史是UTUC根治术后出现膀胱复发的独立危险因素。临床医师应着重关注存在上述危险因素的UTUC术后患者，做好定期随访。</p></sec><sec id="s2"><title>关键词</title><p>上尿路尿路上皮癌，膀胱复发，危险因素</p></sec><sec id="s3"><title>Risk Factors for Intravesical Recurrence after the Surgery of Upper Tract Urothelial Carcinoma<sup> </sup></title><p>Kewei Han<sup>1*</sup>, Qinchao Yu<sup>2#</sup>, Xiangyu Li<sup>1</sup>, Xingchao Pei<sup>1</sup></p><p><sup>1</sup>Qingdao Medical College of Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Department of Urology, Laoshan District Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/48-1572414x5_hanspub.png?20210727090329849" /></p><p>Received: Jun. 21<sup>st</sup>, 2021; accepted: Jul. 11<sup>th</sup>, 2021; published: Jul. 26<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/48-1572414x6_hanspub.png?20210727090329849" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To investigate the risk factors for intravesical recurrence in patients after the surgery of upper tract urothelial carcinomas (UTUCs). Methods: Clinical data of 127 UTUC patients were collected who underwent full-length nephroureter plus bladder sleeve resection in Affiliated Hospital of Qingdao University during Jan. 2015 to Dec. 2016. The baseline data, postoperative pathological results and follow-up data were analyzed. Chi-square test and logistic regression were used to analyze the risk factors of intravesical recurrence in patients with UTUC after the surgery. Result: In this study, 28 cases of 127 patients were diagnosed intravesical recurrence after radical operation of UTUC, the recurrence rate was 22.0% (28/127), of which 67.9% (19/28) patients had intravesical recurrence within 2 years after operation. There was no significant difference in the incidence of intravesical recurrence among different gender, age, tumor location and size, pathological stage and tumor side (P &gt; 0.05). There was a significant difference in intravesical recurrence between patients undergoing ureteroscopy before the surgery and a history of bladder cancer before operation (P &lt; 0.05), which was regarded as a risk factor for intravesical recurrence. Logistic regression analysis showed that the above risk factors were independent risk factors for intravesical recurrence after radical operation of UTUC. Conclusion: Ureteroscopy before the surgery and history of bladder cancer are independent risk factors for intravesical recurrence after UTUC radical resection. Clinicians should pay more attention to the patients with the above risk factors after UTUC, and make regular follow-up.</p><p>Keywords:Upper Tract Urothelial Carcinoma, Intravesical Recurrence, Risk Factor</p><disp-formula id="hanspub.44147-formula24"><graphic xlink:href="//html.hanspub.org/file/48-1572414x7_hanspub.png?20210727090329849"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/48-1572414x8_hanspub.png?20210727090329849" /> <img src="//html.hanspub.org/file/48-1572414x9_hanspub.png?20210727090329849" /></p></sec><sec id="s5"><title>1. 引言</title><p>上尿路尿路上皮癌(upper tract urothelial carcinoma, UTUC)是发病率较低的泌尿系统恶性肿瘤，范围可以位于肾盂、肾盏及输尿管，仅仅占全部尿路上皮癌的5%~10% [<xref ref-type="bibr" rid="hanspub.44147-ref1">1</xref>]。在我国，上尿路尿路上皮癌发病人群具有独特的发病机制及临床特征：受含马兜铃酸中草药的影响，中国UTUC人群肿瘤恶性程度相对较低，且具有较好的预后 [<xref ref-type="bibr" rid="hanspub.44147-ref2">2</xref>]。UTUC的临床治疗推荐手术治疗，金标准为患侧肾输尿管全长切除加膀胱袖套状切除术 [<xref ref-type="bibr" rid="hanspub.44147-ref3">3</xref>]，然而术后会有一定概率会出现肿瘤复发，其中最常见的部位发生在膀胱，其概率为22%~47% [<xref ref-type="bibr" rid="hanspub.44147-ref4">4</xref>]。本研究共纳入了127例行UTUC根治术的患者，目的在于通过分析比较其不同的临床资料，得出膀胱复发的危险因素，从而指导UTUC患者根治术后的后续治疗及随访。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 临床资料</title><p>通过His系统及联众数字病案管理系统，以“肾盂恶性肿瘤”、“肾盂癌”、“输尿管恶性肿瘤”、“输尿管癌”、“肾盂肿物”、“输尿管肿物”等关键词为搜索条件，时间限定为2015年1月至2016年12月，收集在此期间青岛大学附属医院收治的UTUC患者。纳入标准：① 术前症状及影像学检查提示肾盂肾盏或输尿管占位性病变；② 术前未接受过放化疗等肿瘤相关治疗；③ 术后病理确诊为UTUC。排除标准：① 合并其他恶性肿瘤；② 临床及病历资料不完整及缺失；③ 双侧上尿路尿路上皮癌。根据以上标准，本研究共收集了127例UTUC患者的临床资料，其中，男92例，女35例；年龄为35~85岁，平均年龄为(67.63 &#177; 10.43)岁；79例患者以血尿为唯一症状，16例查体发现，15例以单纯腰痛为症状，17例在腰痛的同时伴发血尿。收集患者的性别、年龄、病理分期、病理分级、肿瘤位置、肿瘤直径、术前是否进行输尿管镜检查的临床资料。所有患者均行开放、腹腔镜或者达芬奇机器人辅助下肾输尿管全长切除术加膀胱袖套状切除术，患者术后病理结果均证实为上尿路尿路上皮癌。</p></sec><sec id="s6_2"><title>2.2. 膀胱灌注及术后复查方案</title><p>所有患者在根治术后均行规律的膀胱灌注治疗，方案包括吡柔比星、表柔比星、吉西他滨等，基本方案为1周1次 &#215; 8次，1月1次 &#215; 8次。所有患者术后每三个月复查一次膀胱镜，每半年复查一次泌尿系统超声，至少坚持2年。</p></sec><sec id="s6_3"><title>2.3. 随访及观察指标</title><p>查询到符合纳入和排除标准患者的所有临床资料，随访方式包括电话询问、门诊记录查询、电子病历翻阅等，随访时间为3~62个月，中位随访时间为35个月；随访内容重点关注患者有无出现膀胱复发，如出现复发，有无行手术治疗以获取病理结果。对于出现血尿、腰痛、下尿路症状的患者，则及时完善超声、CT、膀胱镜检查等相关检查。膀胱复发的定义为病理确诊为膀胱癌，本研究中，出现膀胱复发的患者共28例，其中26例行膀胱镜检查以及膀胱病损切除术，2例行膀胱癌根治术，术后病理送检以确诊。</p></sec><sec id="s6_4"><title>2.4. 统计学方法</title><p>将收集到的临床资料以数据形式录入进SPSS 26.0软件并进行统计分析。符合正态分布的计量资料以均数&#177;标准差表示，计数资料以例数和率表示，对可能的危险因素应用χ<sup>2</sup>检验进行单因素分析，将其中有意义的因素纳入logistics回归分析，筛选出UTUC根治术后出现膀胱复发的危险因素。以P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 比较不同临床资料的UTUC患者根治术后出现膀胱复发的情况</title><p>本研究中，行UTUC根治术的患者出现膀胱复发的有28例，其中19例发生在术后2年内，而未复发的例数为99例，得出膀胱复发率为22.0% (28/127)。在28例复发膀胱癌的患者中，10例因血尿就诊，16例由定期膀胱镜检查或影像学复查发现，1例因排尿困难就诊，1例因脚部水肿就诊。单因素分析结果显示：不同年龄、性别、肿瘤的侧别、位置、直径以及术后病理的分期和分级的UTUC根治术后膀胱复发的概率相比较，差异均无统计学意义(P &gt; 0.05)；是否合并膀胱癌病史、根治术前是否进行输尿管镜检查的UTUC根治术后患者的膀胱复发率相比较，其差异具有统计学意义(P &lt; 0.05)。详见表1。</p></sec><sec id="s7_2"><title>3.2. UTUC患者术后出现膀胱复发的Logistics回归分析</title><p>将单因素分析中的差异具有统计学意义部分纳入Logistics回归分析中，出现如下结果，得出的结论为：合并膀胱癌病史、术前行输尿管镜检查为UTUC根治术后患者出现膀胱复发的独立危险因素(P &lt; 0.05)。详见表2。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of intravesical recurrence in patients with different clinical characteristics of UTUC after radical surgery (n = 127</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >临床资料</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >膀胱复发n (%)</th><th align="center" valign="middle" >χ<sup>2</sup>值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1.694</td><td align="center" valign="middle" >0.193</td></tr><tr><td align="center" valign="middle" >男</td><td align="center" valign="middle" >92</td><td align="center" valign="middle" >23 (25.0)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >5 (14.3)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.004</td><td align="center" valign="middle" >0.950</td></tr><tr><td align="center" valign="middle" >≥65</td><td align="center" valign="middle" >81</td><td align="center" valign="middle" >18 (22.2)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;65</td><td align="center" valign="middle" >46</td><td align="center" valign="middle" >10 (21.7)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >合并膀胱癌</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >17.505</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >是</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >7 (77.8)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >否</td><td align="center" valign="middle" >118</td><td align="center" valign="middle" >21 (17.8)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >肿瘤侧别</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2.481</td><td align="center" valign="middle" >0.115</td></tr><tr><td align="center" valign="middle" >左</td><td align="center" valign="middle" >71</td><td align="center" valign="middle" >12 (16.9)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >右</td><td align="center" valign="middle" >56</td><td align="center" valign="middle" >16 (28.6)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >输尿管镜检</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4.741</td><td align="center" valign="middle" >0.029</td></tr><tr><td align="center" valign="middle" >是</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >12 (35.3)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >否</td><td align="center" valign="middle" >93</td><td align="center" valign="middle" >16 (17.2)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >肿瘤部位</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.913</td><td align="center" valign="middle" >0.339</td></tr><tr><td align="center" valign="middle" >肾盂</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >11 (18.3)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >输尿管</td><td align="center" valign="middle" >67</td><td align="center" valign="middle" >17 (25.4)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >病理分期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1.583</td><td align="center" valign="middle" >0.208</td></tr><tr><td align="center" valign="middle" >≤T2</td><td align="center" valign="middle" >73</td><td align="center" valign="middle" >19 (26.0)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&gt;T2</td><td align="center" valign="middle" >54</td><td align="center" valign="middle" >9 (16.7)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >病理分级</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.703</td><td align="center" valign="middle" >0.402</td></tr><tr><td align="center" valign="middle" >低级别</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >7 (17.5)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >高级别</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >21 (24.1)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >肿瘤直径(cm)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.550</td><td align="center" valign="middle" >0.458</td></tr><tr><td align="center" valign="middle" >&lt;3</td><td align="center" valign="middle" >39</td><td align="center" valign="middle" >7 (17.9)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥3</td><td align="center" valign="middle" >88</td><td align="center" valign="middle" >21 (25.9)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表1. 不同临床特征UTUC患者根治术后膀胱复发的比较(n = 127)</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Logistic regression analysis of intravesical recurrence after radical surgery of UTUC (n = 127</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >因素</th><th align="center" valign="middle" >B</th><th align="center" valign="middle" >SE</th><th align="center" valign="middle" >Wald</th><th align="center" valign="middle" >P值</th><th align="center" valign="middle" >OR (95%CI)</th></tr></thead><tr><td align="center" valign="middle" >输尿管镜检查</td><td align="center" valign="middle" >1.123</td><td align="center" valign="middle" >0.488</td><td align="center" valign="middle" >5.291</td><td align="center" valign="middle" >0.021</td><td align="center" valign="middle" >3.075 (1.181, 8.009)</td></tr><tr><td align="center" valign="middle" >合并膀胱癌</td><td align="center" valign="middle" >2.990</td><td align="center" valign="middle" >0.862</td><td align="center" valign="middle" >12.044</td><td align="center" valign="middle" >0.001</td><td align="center" valign="middle" >19.883 (3.674, 107.596)</td></tr></tbody></table></table-wrap><p>表2. UTUC根治术后出现膀胱复发的Logistics回归分析(n = 127)</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>在我国，UTUC占全部尿路上皮癌的比例比起欧美人群更高(2018年全国32家中心住院患者的初步调查结果显示，UTUC占尿路上皮癌的比例为9.3%~29.9%，平均17.9%) [<xref ref-type="bibr" rid="hanspub.44147-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.44147-ref5">5</xref>]。虽然目前缺乏膀胱复发对于上尿路尿路上皮癌预后有影响的确切证据，早期的基于长期随访数据的回顾性研究均未发现膀胱复发与患者生存存在相关性 [<xref ref-type="bibr" rid="hanspub.44147-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.44147-ref7">7</xref>]，但膀胱复发给患者带来了心理及经济上沉重的负担，不可不作为一个值得研究的问题。UTUC最为推荐的治疗方式为患侧肾输尿管全长切除术加膀胱袖套状切除术，术中应注意完成输尿管膀胱壁内部分和输尿管口的切除，并尽量保证尿道的完整性，可是在术后会发生泌尿系及泌尿系外的复发 [<xref ref-type="bibr" rid="hanspub.44147-ref8">8</xref>]。而膀胱是UTUC根治术后复发的最常见部位，且大多数研究一致认为，80%~90%的膀胱复发出现在UTUC根治术后的2年内 [<xref ref-type="bibr" rid="hanspub.44147-ref9">9</xref>]，故探讨其UTUC根治术后出现膀胱复发的危险因素对于实现UTUC患者的危险分层、预后判断、随访策略制定有重要意义。《欧洲泌尿外科协会UTUC诊治指南》将UTUC术后膀胱复发危险因素分为3类：(1) 患者相关因素，包括性别、膀胱癌病史、术前慢性肾脏疾病等；(2) 肿瘤相关因素，包括术前尿脱落细胞学、肿瘤位置和分期、是否为多发肿瘤等；(3) 治疗相关因素，包括腹腔镜手术、阳性切缘、膀胱袖套状切除术等 [<xref ref-type="bibr" rid="hanspub.44147-ref10">10</xref>]。</p><p>UTUC术后膀胱复发的危险因素尚未被阐明，但目前认为UTUC的肿瘤多灶性和膀胱癌病史是与膀胱肿瘤复发密切相关的2个重要危险因素 [<xref ref-type="bibr" rid="hanspub.44147-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.44147-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.44147-ref13">13</xref>]。与该共识相同，本研究发现膀胱癌病史是UTUC术后膀胱复发的危险因素，然而，由于膀胱肿瘤自身的特性原因，它有着较高的复发率，Maurice等 [<xref ref-type="bibr" rid="hanspub.44147-ref14">14</xref>] 人研究发现传统TURBT手术术后复发率高达30%~50%，所以需要进一步的分析以排除膀胱癌本身复发的影响。而本研究中仅有2例为多发性肿瘤，其他均为单灶性肿瘤，不构成作为危险因素的分析条件，故未将该因素列入比较范围。Yuan等 [<xref ref-type="bibr" rid="hanspub.44147-ref11">11</xref>] 的Meta分析结果认为UTUC的肿瘤大小、分期、肿瘤位置、患者性别是膀胱复发的危险因素，而肿瘤的分级、患者的年龄则与膀胱复发没有统计学意义。而Seisen等 [<xref ref-type="bibr" rid="hanspub.44147-ref12">12</xref>] 的Meta分析则认为低分级的UTUC与膀胱复发有关，同时也支持危险因素为患者性别、肿瘤位置等。关豹等 [<xref ref-type="bibr" rid="hanspub.44147-ref15">15</xref>] 认为，膀胱复发灶肿瘤肌层浸润和高级别常发生于原发UTUC肌层浸润的患者，女性与男性相比容易发生多次膀胱复发；原发UTUC肌层浸润是UTUC膀胱复发患者肿瘤特异性生存的独立危险因素。任乾等 [<xref ref-type="bibr" rid="hanspub.44147-ref16">16</xref>] 通过对长海医院的445例UTUC患者进行分析，得出的结论为：结论年龄 ≥ 65岁、有膀胱癌病史、行保留肾单位肿瘤局部切除术、输尿管下段肿瘤是UTUC术后膀胱复发的独立危险因素。从理论上来分析以上因素，分期越高的肿瘤其侵袭性越强，体积较大的上尿路肿瘤也更有机会发生脱落和播种，从而引起膀胱复发；低级别的肿瘤更容易出现腔内种植转移；而输尿管肿瘤的位置相较肾盂肿瘤更接近膀胱，因此与膀胱复发的相关性更大。然而，本研究不支持以上所述危险因素，这可能受患者本身因素如年龄、生活习惯、其他疾病等的影响，本研究所纳入患者数量有限、时间跨度较短。因此需要更大样本、更长时间跨度的数据来行进一步的分析，以排除此类误差带来的影响。</p><p>对于诊断性输尿管镜检查是否增加UTUC术后膀胱复发，存在不同的声音，本研究发现术前输尿管镜检查是术后膀胱复发的危险因素。Marchioni等 [<xref ref-type="bibr" rid="hanspub.44147-ref17">17</xref>] 通过Meta分析发现，UTUC术前行诊断性输尿管镜检查组膀胱复发率较未行组明显升高，差异具有统计学意义(P &lt; 0.001)。Yoo等 [<xref ref-type="bibr" rid="hanspub.44147-ref6">6</xref>] 对387例UTUC患者资料进行分析，得出的结论是输尿管镜检查不增加输尿管癌患者术后膀胱复发风险，但肾盂癌患者行输尿管镜检查后膀胱复发率较输尿管癌组明显升高(P = 0.012)。Lee等 [<xref ref-type="bibr" rid="hanspub.44147-ref18">18</xref>] 发现行诊断性输尿管镜检查后即行根治术不会增加膀胱复发风险，而在间隔5天以后则会增加。值得一提的是，欧洲泌尿外科协会(EAU)上尿路尿路上皮癌指南：2020更新已将诊断性输尿管镜检查作为一项危险因素写入其中 [<xref ref-type="bibr" rid="hanspub.44147-ref19">19</xref>]。诊断性输尿管镜检查的意义在于明确上尿路占位性病变的性质，取活检后可以明确病理诊断并为行根治术提供证据，是严格意义上唯一可以在手术切除前进行确诊的手段。而随着影像学技术的进步，增强CT的诊断敏感性可达67%~100%，特异性可达93%~99% [<xref ref-type="bibr" rid="hanspub.44147-ref20">20</xref>]，而且上述诸多证据提示了诊断性输尿管镜检查有增加术后膀胱复发概率的可能性，因此对于该项检查的必要性需要临床医师的重新考量。</p><p>综上，收集2015.1至2016.12期间青岛大学附属医院满足纳入和排除标准的127例患者中，123例患者采用了腹腔镜手术方式，且术前行尿脱落细胞学的例数为57例，并不能够满足纳入分析的条件，而近年来，对诊断性输尿管镜检查是否增加UTUC术后膀胱复发的研究有所增加。所以本文针对年龄、性别、是否合并膀胱癌、肿瘤的侧别、位置、直径以及病理分级和分期、是否进行术前输尿管镜检这9个因素加以分析，得出的结论是UTUC根治术后的膀胱复发的危险因素为术前输尿管镜检及患者合并膀胱癌病史。临床医师需要密切关注术前伴发膀胱癌的患者，重视对此类患者的术后随访，尽早发现可能存在的术后会发生膀胱癌的患者。而对于诊断明确的上尿路尿路上皮癌，术前诊断性输尿管镜检查可不必作为一项必须的检查项目；对于诊断未能明确的患者，需综合考虑其膀胱复发的危险程度，酌情给予此项检查。不过，本研究为回顾性的单中心研究，证据等级不高，同时存在样本量小，随访时间短等问题，难免会出现一定程度上的研究结果的偏倚，所以仍然需要前瞻性的、多中心研究来证明其可靠性；另外，本研究未纳入UTUC根治术后出现膀胱复发的保护性因素的分析，如术后即刻的膀胱灌注、术中无瘤技术的应用、放疗等，在未来也会逐渐将这几项纳入研究。</p></sec><sec id="s9"><title>文章引用</title><p>韩克威,于芹超,李翔宇,裴兴超. 上尿路尿路上皮癌术后出现膀胱复发的危险因素分析Risk Factors for Intravesical Recurrence after the Surgery of Upper Tract Urothelial Carcinoma[J]. 临床医学进展, 2021, 11(07): 3218-3224. https://doi.org/10.12677/ACM.2021.117467</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44147-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Rouprêt, M., Babjuk, M., Compérat, E., Zigeuner, R., Sylvester, R.J., Burger, M., Cowan, N.C., Gontero, P., Van Rhijn, B.W.G., Mostafid, A.H., Palou, J. and Shariat, S.F. (2018) European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. European Urology, 73, 111-122. 
&lt;br&gt;https://doi.org/10.1016/j.eururo.2017.07.036</mixed-citation></ref><ref id="hanspub.44147-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">周利群, 李学松, 熊耕砚. 中国人群上尿路尿路上皮癌新进展[J]. 北京大学学报(医学版), 2014, 46(4): 504-506.</mixed-citation></ref><ref id="hanspub.44147-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Audenet, F., Yates, D.R., Cussenot, O. and Rouprêt, M. (2013) The Role of Chemotherapy in the Treatment of Urothelial Cell Carcinoma of the Upper Urinary Tract (UUT-UCC). Urologic Oncology: Seminars and Original Investigations, 31, 407-413. &lt;br&gt;https://doi.org/10.1016/j.urolonc.2010.07.016</mixed-citation></ref><ref id="hanspub.44147-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Xylinas, E., Rink, M., Margulis, V., Karakiewicz, P., Novara, G. and Shariat, S.F. (2012) Multifocal Carcinoma in situ of the Upper Tract Is Associated with High Risk of Bladder Cancer Recurrence. European Urology, 61, 1069-1070. 
&lt;br&gt;https://doi.org/10.1016/j.eururo.2012.02.042</mixed-citation></ref><ref id="hanspub.44147-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">方冬, 李学松. 上尿路尿路上皮癌诊断与治疗中国专家共识[J]. 中华泌尿外科杂志, 2018, 39(7): 485-488.</mixed-citation></ref><ref id="hanspub.44147-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Sakamoto, N., Naito, S., Kotoh, S., Nakashima, M., Nakamura, M., Ueda, T. and Kumazawa, J. (1991) Recurrence of Bladder Tumors Following Surgery for Transitional Cell Carcinoma of the Upper Urinary Tract. European Urology, 20, 136-139. &lt;br&gt;https://doi.org/10.1159/000471683</mixed-citation></ref><ref id="hanspub.44147-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Charbit, L., Gendreau, M.C., Mee, S. and Cukier, J. (1991) Tumors of the Upper Urinary Tract: 10 Years of Experience. The Journal of Urology, 146, 1243-1246. &lt;br&gt;https://doi.org/10.1016/S0022-5347(17)38059-X</mixed-citation></ref><ref id="hanspub.44147-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Milojevic, B., Dzamic, Z., Kajmakovic, B., Milenkovic Petronic, D. and Sipetic Grujicic, S. (2015) Urothelial Carcinoma: Recurrence and Risk Factors. Journal of BUON: Official Journal of the Balkan Union of Oncology, 20, 391-398.</mixed-citation></ref><ref id="hanspub.44147-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">van der Poel, H.G., Antonini, N., van Tinteren, H. and Horenblas, S. (2005) Upper Urinary Tract Cancer: Location Is Correlated with Prognosis. European Urology, 48, 438-444. &lt;br&gt;https://doi.org/10.1016/j.eururo.2005.03.009</mixed-citation></ref><ref id="hanspub.44147-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Rouprêt, M., Babjuk, M., Compérat, E., Zigeuner, R., Sylvester, R.J., Burger, M., Cowan, N.C., Böhle, A., Van Rhijn, B.W., Kaasinen, E., Palou, J. and Shariat, S.F. (2015) European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. European Urology, 68, 868-879.  
&lt;br&gt;https://doi.org/10.1016/j.eururo.2015.06.044</mixed-citation></ref><ref id="hanspub.44147-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Yuan, H., Chen, X., Liu, L., Yang, L., Pu, C., Li, J., Bai, Y., Han, P. and Wei, Q. (2014) Risk Factors for Intravesical Recurrence after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Meta-Analysis. Urologic Oncology, 32, 989-1002. &lt;br&gt;https://doi.org/10.1016/j.urolonc.2014.01.022</mixed-citation></ref><ref id="hanspub.44147-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Seisen, T., Granger, B., Colin, P., Léon, P., Utard, G., Renard-Penna, R., Compérat, E., Mozer, P., Cussenot, O., Shariat, S.F. and Rouprêt, M. (2015) A Systematic Review and Meta-analysis of Clinicopathologic Factors Linked to Intravesical Recurrence after Radical Nephroureterectomy to Treat Upper Tract Urothelial Carcinoma. European Urology, 67, 1122-1133. &lt;br&gt;https://doi.org/10.1016/j.eururo.2014.11.035</mixed-citation></ref><ref id="hanspub.44147-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">邢云超, 熊耕砚, 方东, 张争, 蔡林, 张雷, 何志嵩, 李学松, 周利群. 上尿路尿路上皮癌术前预后相关因素分析及初步风险分层模型构建[J]. 北京大学学报(医学版), 2016, 48(6): 1032-1037.</mixed-citation></ref><ref id="hanspub.44147-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Maurice, M.J., Vricella, G.J., MacLennan, G., Buehner, P. and Ponsky, L.E. (2012) Endoscopic Snare Resection of Bladder Tumors: Evaluation of an Alternative Technique for Bladder Tumor Resection. Journal of Endourology, 26, 614-617. &lt;br&gt;https://doi.org/10.1089/end.2011.0587</mixed-citation></ref><ref id="hanspub.44147-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">关豹, 曹振朋, 彭鼎, 李一帆, 詹永豪, 何世明, 巩艳青, 方冬, 张雷, 熊耕砚, 李学松, 周利群. 上尿路尿路上皮癌患者膀胱复发灶的危险因素分析[J]. 中华泌尿外科杂志, 2017, 38(12): 896-900.</mixed-citation></ref><ref id="hanspub.44147-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">任乾, 曾蜀雄, 汤仕杰, 戴利和, 徐金山, 孙颖浩, 许传亮. 上尿路尿路上皮癌术后膀胱复发危险因素分析[J]. 第二军医大学学报, 2018, 39(5): 469-473.</mixed-citation></ref><ref id="hanspub.44147-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Marchioni, M., Primiceri, G., Cindolo, L., Hampton, L.J., Grob, M.B., Guruli, G., Schips, L., Shariat, S.F. and Autorino, R. (2017) Impact of Diagnostic Ureteroscopy on Intravesical Recurrence in Patients Undergoing Radical Nephroureterectomy for Upper Tract Urothelial Cancer: A Systematic Review and Meta-Analysis. BJU International, 120, 313-319. &lt;br&gt;https://doi.org/10.1111/bju.13935</mixed-citation></ref><ref id="hanspub.44147-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Lee, J.K., Kim, K.B., Park, Y.H., Oh, J.J., Lee, S., Jeong, C.W., Jeong, S.J., Hong, S.K., Byun, S.S. and Lee, S.E. (2016) Correlation between the Timing of Diagnostic Ureteroscopy and Intravesical Recurrence in Upper Tract Urothelial Cancer. Clinical Genitourinary Cancer, 14, 37-41. &lt;br&gt;https://doi.org/10.1016/j.clgc.2015.07.008</mixed-citation></ref><ref id="hanspub.44147-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Rouprêt, M., Babjuk, M., Burger, M., Capoun, O., Cohen, D., Compérat, E.M., Cowan, N.C., Dominguez-Escrig, J.L., Gontero, P., Hugh Mostafid, A., Palou, J., Peyronnet, B., Seisen, T., Soukup, V., Sylvester, R.J., Rhijn, B., Zigeuner, R. and Shariat, S.F. (2021) European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. European Urology, 79, 62-79. &lt;br&gt;https://doi.org/10.1016/j.eururo.2020.05.042</mixed-citation></ref><ref id="hanspub.44147-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Cowan, N.C., Turney, B.W., Taylor, N.J., McCarthy, C.L. and Crew, J.P. (2007) Multidetector Computed Tomography Urography for Diagnosing Upper Urinary Tract Urothelial Tumour. BJU International, 99, 1363-1370. 
&lt;br&gt;https://doi.org/10.1111/j.1464-410X.2007.06766.x</mixed-citation></ref></ref-list></back></article>